Summary Intersect ENT Inc. (Intersect), formerly Sinexus, Inc. is a medical equipment company that offers chronic sinusitis solutions. The company offers steroid releasing implants and mini steroid implants. Its products are used in chronic sinusitis treatment such as facial pain or pressure, nasal congestion or obstruction, loss of smell or taste, headache, discolored nasal discharge, loss of sleep or fatigue and depression. Intersect provides treatment through medical therapy and sinus surgery. Intersect has developed the propel steroid-releasing implant. The company distributes its products in domestic and overseas markets. Intersect is headquartered in Menlo Park, California, the US. This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Scope: - The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments - The report analyzes all pipeline products in development for the company Intersect ENT Inc. - The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) - The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date - The report provides detailed description of products in development, technical specification and functions - The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date. Reasons to Buy: - Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape - Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio - To formulate effective Research & Development strategies - Develop market-entry and market expansion strategies - Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc - Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Intersect ENT Inc. Company Snapshot 6 Intersect ENT Inc. Company Overview 6 Intersect ENT Inc. Pipeline Products and Clinical Trials Overview 7 Intersect ENT Inc. - Pipeline Analysis Overview 9 Key Facts 9 Intersect ENT Inc. - Major Products and Services 10 Intersect ENT Inc. Pipeline Products by Development Stage 11 Intersect ENT Inc. Clinical Trials by Trial Status 13 Intersect ENT Inc. Pipeline Products Overview 14 NOVA - Frontal Indication 14 NOVA - Frontal Indication Product Overview 14 NOVA - Frontal Indication Clinical Trial 15 NOVA- Maxillary Indication 16 NOVA- Maxillary Indication Product Overview 16 Propel Implant - Frontal Indication 17 Propel Implant - Frontal Indication Product Overview 17 Resolve- Ethmoid Sinus 18 Resolve- Ethmoid Sinus Product Overview 18 Steroid-Releasing S8 Sinus Implant 19 Steroid-Releasing S8 Sinus Implant Product Overview 19 Steroid-Releasing S8 Sinus Implant Clinical Trial 20 Intersect ENT Inc. - Key Competitors 21 Intersect ENT Inc. - Key Employees 22 Intersect ENT Inc. - Locations And Subsidiaries 23 Head Office 23 Recent Developments 24 Intersect ENT Inc., Recent Developments 24 Jun 01, 2016: Intersect ENT Announces Completion of Enrollment in RESOLVE II Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis 24 May 16, 2016: Intersect ENT Announces Positive Clinical Results From Pivotal Study of Newest Steroid Releasing Sinus Implant 24 May 05, 2016: Intersect ENT Reports First Quarter 2016 Results 25 Mar 23, 2016: Intersect ENT Announces FDA Approval Of Additional Indication For PROPEL Mini Sinus Implant 26 Feb 23, 2016: Intersect ENT Reports Fourth Quarter and Year 2015 Results 27 Feb 22, 2016: Intersect ENT Appoints David Lehman General Counsel 28 Jan 29, 2016: Intersect ENT Announces NUB Status 1 Designation for PROPEL Sinus Implant in Germany 28 Jan 11, 2016: Intersect ENT Reports Preliminary Q4 and Year 2015 Revenue 28 Nov 10, 2015: Intersect ENT Announces Data Further Demonstrating Health Economic Value of PROPEL Steroid Releasing Implants 29 Nov 04, 2015: Intersect ENT Reports Third Quarter 2015 Results 29 Appendix 31 Methodology 31 About GlobalData 31 Contact Us 31 Disclaimer 31
List of Tables
Intersect ENT Inc. Pipeline Products and Clinical Trials Overview 7 Intersect ENT Inc. Pipeline Products by Equipment Type 7 Intersect ENT Inc. Pipeline Products by Indication 8 Intersect ENT Inc. Clinical Trials by Trial Status 8 Intersect ENT Inc., Key Facts 9 Intersect ENT Inc., Major Products and Services 10 Intersect ENT Inc. Number of Pipeline Products by Development Stage 11 Intersect ENT Inc. Pipeline Products Summary by Development Stage 12 Intersect ENT Inc. Clinical Trials by Trial Status 13 Intersect ENT Inc. Clinical Trials Summary 13 NOVA - Frontal Indication - Product Status 14 NOVA - Frontal Indication - Product Description 14 NOVA - Frontal Indication - Pivotal Study to Evaluate the NOVA Sinus Implant 15 NOVA- Maxillary Indication - Product Status 16 NOVA- Maxillary Indication - Product Description 16 Propel Implant - Frontal Indication - Product Status 17 Propel Implant - Frontal Indication - Product Description 17 Resolve- Ethmoid Sinus - Product Status 18 Resolve- Ethmoid Sinus - Product Description 18 Steroid-Releasing S8 Sinus Implant - Product Status 19 Steroid-Releasing S8 Sinus Implant - Product Description 19 Steroid-Releasing S8 Sinus Implant - A Clinical Evaluation of the Safety and Efficacy of the Steroid-Releasing S8 Sinus Implant in Chronic Sinusitis Patients With Recurrent Sinus Obstruction (RESOLVE II) 20 Intersect ENT Inc., Key Employees 22
List of Figures
Intersect ENT Inc. Pipeline Products by Equipment Type 8 Intersect ENT Inc. Pipeline Products by Development Stage 11 Intersect ENT Inc. Clinical Trials by Trial Status 13
U.S hairbrush market is estimated to exceed USD 1.2 billion by 2022, as per a new research report by Radiant Insights, Inc. Rising population along with ascending disposable income is expected to drive industry demand. Significant rise in disposableRead More...
Global aerospace plastics market size is likely to be valued at USD 13.48 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing application scope of lightweight materials in aerospace industry is likely to drive market growtRead More...
Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing apRead More...
Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehiRead More...
Global air traffic control equipment market is projected to reach USD 4.2 billion by 2020, as per a new research report by Radiant Insights, Inc. Mounting price sensitivity among customers with introduction of low fare airlines is expected to drive tRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.